Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics (PTHS) announced expanded formulary coverage for ZELSUVMI, its topical gel for molluscum contagiosum. The company added 24M covered lives via a major PBM and 3M via a regional health plan, increasing total coverage to 127M commercially insured lives. ZELSUVMI, launched in July 2025, is the first FDA-approved at-home treatment for the skin infection.
How this was made
The 30-second read
Why it matters
The expanded formulary access removes prior‑authorization barriers, potentially accelerating adoption and revenue growth.
Market read
First‑time disclosure of a sizable formulary expansion for a niche dermatology drug, likely to move the stock modestly.
What to watch
The product’s reliance on a single PBM partnership could expose revenue to future contract renegotiations.
Background
Pelthos Therapeutics (PTHS) is a commercial‑stage biotech focused on cutaneous infectious diseases. ZELSUVMI is its lead product for molluscum contagiosum.
Ticker impact
Pelthos Therapeutics announced expanded formulary coverage for ZELSUVMI, adding 24 million PBM lives and reaching 127 million commercially covered lives.
likely upward pressure as investors price in larger patient access.
New formulary agreements with a major PBM and a regional health plan increase addressable market; no prior coverage disclosed.
Market effects
Strengthens the dermatology/dermatologic‑infectious‑disease niche and may benefit peers with similar topical therapies.
U.S. market, especially insurers and PBMs, sees broader coverage of a novel molluscum treatment.
Limited to U.S. healthcare market; minimal global spillover.
Counterpoint
Coverage gains may be offset by reimbursement pressure or competition from emerging over‑the‑counter treatments.
Key entities
- companyPelthos Therapeutics Inc.
Biopharma developing ZELSUVMI.
- partnerMajor Pharmacy Benefit Manager
Unnamed PBM covering ~24 million lives.
